Literature DB >> 20534477

A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.

Sang Hyun Lee1, George Poulogiannis, Saumyadipta Pyne, Shidong Jia, Lihua Zou, Sabina Signoretti, Massimo Loda, Lewis Clayton Cantley, Thomas M Roberts.   

Abstract

Recent work has shown that ablation of p110beta, but not p110alpha, markedly impairs tumorigenesis driven by loss of phosphatase and tensin homolog (PTEN) in the mouse prostate. Other laboratories have reported complementary data in human prostate tumor lines, suggesting that p110beta activation is necessary for tumorigenesis driven by PTEN loss. Given the multiple functions of PTEN, we wondered if p110beta activation also is sufficient for tumorigenesis. Here, we report that transgenic expression of a constitutively activated p110beta allele in the prostate drives prostate intraepithelial neoplasia formation. The resulting lesions are similar to, but are clearly distinct from, the ones arising from PTEN loss or Akt activation. Array analyses of transcription in multiple murine prostate tumor models featuring PI3K/AKT pathway activation allowed construction of a pathway signature that may be useful in predicting the prognosis of human prostate tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20534477      PMCID: PMC2890726          DOI: 10.1073/pnas.1005642107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  52 in total

1.  Role of p63 and basal cells in the prostate.

Authors:  Takeshi Kurita; Roanna T Medina; Alea A Mills; Gerald R Cunha
Journal:  Development       Date:  2004-09-15       Impact factor: 6.868

2.  High frequency of mutations of the PIK3CA gene in human cancers.

Authors:  Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Science       Date:  2004-03-11       Impact factor: 47.728

3.  Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase.

Authors:  L Bi; I Okabe; D J Bernard; A Wynshaw-Boris; R L Nussbaum
Journal:  J Biol Chem       Date:  1999-04-16       Impact factor: 5.157

4.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.

Authors:  H Suzuki; D Freije; D R Nusskern; K Okami; P Cairns; D Sidransky; W B Isaacs; G S Bova
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

5.  Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas.

Authors:  S I Wang; R Parsons; M Ittmann
Journal:  Clin Cancer Res       Date:  1998-03       Impact factor: 12.531

6.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy.

Authors:  Yan Ping Yu; Douglas Landsittel; Ling Jing; Joel Nelson; Baoguo Ren; Lijun Liu; Courtney McDonald; Ryan Thomas; Rajiv Dhir; Sydney Finkelstein; George Michalopoulos; Michael Becich; Jian-Hua Luo
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

7.  Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate.

Authors:  Christopher Sweeney; Lang Li; Rajasubramaniam Shanmugam; Poornima Bhat-Nakshatri; Vetrichelvan Jayaprakasan; Lee Ann Baldridge; Thomas Gardner; Martin Smith; Harikrishna Nakshatri; Liang Cheng
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

8.  Pten is essential for embryonic development and tumour suppression.

Authors:  A Di Cristofano; B Pesce; C Cordon-Cardo; P P Pandolfi
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

9.  Gene expression profiling predicts clinical outcome of prostate cancer.

Authors:  Gennadi V Glinsky; Anna B Glinskii; Andrew J Stephenson; Robert M Hoffman; William L Gerald
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

10.  Trefoil factor 3 is overexpressed in human prostate cancer.

Authors:  Isla P Garraway; David Seligson; Jonathan Said; Steve Horvath; Robert E Reiter
Journal:  Prostate       Date:  2004-11-01       Impact factor: 4.104

View more
  31 in total

1.  Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.

Authors:  Chenchen He; Shaofeng Duan; Liang Dong; Yifen Wang; Qingting Hu; Chunjing Liu; Marcus L Forrest; Jeffrey M Holzbeierlein; Suxia Han; Benyi Li
Journal:  Prostate       Date:  2017-06-20       Impact factor: 4.104

2.  Protein Kinase C Epsilon Cooperates with PTEN Loss for Prostate Tumorigenesis through the CXCL13-CXCR5 Pathway.

Authors:  Rachana Garg; Jorge M Blando; Carlos J Perez; Martin C Abba; Fernando Benavides; Marcelo G Kazanietz
Journal:  Cell Rep       Date:  2017-04-11       Impact factor: 9.423

Review 3.  The role of phosphoinositide-regulated actin reorganization in chemotaxis and cell migration.

Authors:  C-Y Wu; M-W Lin; D-C Wu; Y-B Huang; H-T Huang; C-L Chen
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

4.  Nanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.

Authors:  Ruibao Chen; Yunqi Zhao; Yan Huang; Qiuhong Yang; Xing Zeng; Wencong Jiang; Jihong Liu; J Brantley Thrasher; M Laird Forrest; Benyi Li
Journal:  Prostate       Date:  2015-01-25       Impact factor: 4.104

5.  Rational Design, Synthesis, and SAR of a Novel Thiazolopyrimidinone Series of Selective PI3K-beta Inhibitors.

Authors:  Hong Lin; Mark J Schulz; Ren Xie; Jin Zeng; Juan I Luengo; Michael D Squire; Rosanna Tedesco; Junya Qu; Karl Erhard; James F Mack; Kaushik Raha; Ramona Plant; Cynthia M Rominger; Jennifer L Ariazi; Christian S Sherk; Michael D Schaber; Jeanelle McSurdy-Freed; Michael D Spengler; Charles B Davis; Mary Ann Hardwicke; Ralph A Rivero
Journal:  ACS Med Chem Lett       Date:  2012-05-29       Impact factor: 4.345

6.  [3a,4]-Dihydropyrazolo[1,5a]pyrimidines: Novel, Potent, and Selective Phosphatidylinositol-3-kinase β Inhibitors.

Authors:  Hongyi Yu; Michael L Moore; Karl Erhard; Mary Ann Hardwicke; Hong Lin; Juan I Luengo; Jeanelle McSurdy-Freed; Ramona Plant; Junya Qu; Kaushik Raha; Cynthia M Rominger; Michael D Schaber; Michael D Spengler; Ralph A Rivero
Journal:  ACS Med Chem Lett       Date:  2013-01-10       Impact factor: 4.345

7.  Transgenic expression of polyomavirus middle T antigen in the mouse prostate gives rise to carcinoma.

Authors:  Sang Hyun Lee; Shidong Jia; Yanni Zhu; Tamara Utermark; Sabina Signoretti; Massimo Loda; Brian Schaffhausen; Thomas M Roberts
Journal:  J Virol       Date:  2011-03-16       Impact factor: 5.103

Review 8.  From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.

Authors:  Chuan Yu; Kevin Hu; Daniel Nguyen; Zhu A Wang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

9.  CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells.

Authors:  Jing Zhang; Xueliang Gao; Fabienne Schmit; Guillaume Adelmant; Michael J Eck; Jarrod A Marto; Jean J Zhao; Thomas M Roberts
Journal:  Cell Rep       Date:  2017-07-18       Impact factor: 9.423

10.  PI3K pathway dependencies in endometrioid endometrial cancer cell lines.

Authors:  Britta Weigelt; Patricia H Warne; Maryou B Lambros; Jorge S Reis-Filho; Julian Downward
Journal:  Clin Cancer Res       Date:  2013-05-14       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.